Literature DB >> 9167507

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

M F Green1, B D Marshall, W C Wirshing, D Ames, S R Marder, S McGurk, R S Kern, J Mintz.   

Abstract

OBJECTIVE: Treatment efficacy in schizophrenia is typically defined in terms of symptom reduction. However, new antipsychotic medications could potentially have an impact on aspects of disability, such as neurocognitive deficits. The authors evaluated the effects of risperidone on verbal working memory, a memory component of theoretical interest because of its link to prefrontal activity and of practical interest because of its link to psychosocial rehabilitation.
METHOD: Verbal working memory of 59 treatment-resistant schizophrenic patients was assessed as part of a randomized, double-blind comparison of treatment with risperidone and haloperidol. Verbal working memory was measured under both distracting and nondistracting conditions at baseline and after 4 weeks of both fixed- and flexible-dose pharmacotherapy.
RESULTS: Risperidone treatment had a greater beneficial effect on verbal working memory than haloperidol treatment across testing conditions (with and without distraction) and study phases (fixed and flexible dose). The treatment effect remained significant after the effects of benztropine cotreatment, change in psychotic symptoms, and change in negative symptoms were controlled. Neither benztropine status nor symptom changes were significantly related to memory performance.
CONCLUSIONS: Treatment with risperidone appears to exert a more favorable effect on verbal working memory than treatment with a conventional neuroleptic. The beneficial effect appears to be due, at least partially, to a direct effect of the drug, possibly through antagonism of the 5-HT2A receptor. Results from this study suggest that pharmacotherapeutic efficacy in schizophrenia treatment could be broadened to include impact on neurocognitive abilities.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9167507     DOI: 10.1176/ajp.154.6.799

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  50 in total

Review 1.  Fortnightly review. Treatment of schizophrenia.

Authors:  J McGrath; W B Emmerson
Journal:  BMJ       Date:  1999-10-16

2.  Cognition, schizophrenia, and the atypical antipsychotic drugs.

Authors:  H Y Meltzer; S Park; R Kessler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 3.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 4.  Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.

Authors:  S E Purdon
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 5.  Treatment-refractory schizophrenia.

Authors:  P F Buckley; L D Wiggins; S Sebastian; B Singer
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 6.  Improving outcome in schizophrenia: the case for early intervention.

Authors:  A K Malla; R M Norman; L P Voruganti
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

7.  Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.

Authors:  Philip D Harvey; Michael F Green; Susan R McGurk; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2003-02-18       Impact factor: 4.530

8.  Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia.

Authors:  Carol J Lane; Elton T C Ngan; Lakshmi N Yatham; Tom J Ruth; Peter F Liddle
Journal:  J Psychiatry Neurosci       Date:  2004-01       Impact factor: 6.186

Review 9.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 10.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.